Fenwick Represents Aceragen in Acquisition by Idera Pharmaceuticals

Fenwick represented Aceragen, a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there are limited or no available treatments, in its acquisition by Idera Pharmaceuticals (Nasdaq: IDRA), a clinical-stage biopharmaceutical company involved in the discovery, development and commercialization of innovative therapeutics for oncology and rare diseases. More information can be obtained from the announcement.

The Fenwick transaction team included corporate partners Rob Freedman, Aman Singh and Ethan Skerry and associates Victoria Lupu, Chelsea Anderson, Rob O'Connor, Beth Clarke, Erica Sun and Atrina Mehdipour; technology transactions partner Jake Handy and associate Kehl Sink; and executive compensation and employee benefits partner Matt Cantor and associate Bryan Belok.